Is Gleevec (imatinib) among the most expensive drugs? Gleevec (imatinib) is widely known as an expensive cancer medicine,… https://www.Drugchatter.com/chat/31710/is-gleevec-the-most-expensive-drug/
DrugChatter: Is gleevec the most expensive drug? Read Post »
Branded generics vs. commodity generics: how brand trust wins market share
In generic drugs, the price gap is obvious. The clinical equivalence is established. So why do some generic products still command a premiumand keep it?
Because in the real worl…
Branded Generics vs. Commodity Generics: How Brand Trust Wins Market Share Read Post »
Pharma has a timing problemand its getting more expensive.
For years, patent strategy was treated like a back-office exercise: file when ready, litigate when necessary, defend when challenged. But the market doesnt wait for your docket. Launch windows …
Dont Get Blind-Sided: The Critical Drug Patent Mistakes to Avoid in MA Due Diligence
In Massachusetts, a single overlooked patent detail can turn a promising acquisition into a costly detourespecially in life sciences, where exclusivity timelines, pate…
Don’t Get Blind-Sided: The Critical Drug Patent Mistakes to Avoid in M&A Due Diligence Read Post »
Post-approval patents are supposed to protect innovation. But in practice, they can also become a quiet, high-stakes Loe risk mapone that investors, brand teams, and generic challengers often only notice after the damage is done.
Heres the hidden probl…
Post-Approval Patents: The Hidden Loe Risk Map Pharma Cant Afford to Ignore
Most teams think the patent story ends at approval.
They shouldnt.
In the post-approval world, the real risk often hides in plain sight: patents that are filed, asserted, or st…
Beyond 20 Years: What Actually Determines a Drugs Market Exclusivity
Most people think drug exclusivity is a simple countdown: patent term ends in ~20 years, then generics arrive. In reality, the market exclusivity clock is more like a relay racemultip…
Beyond 20 Years: What Actually Determines a Drug’s Market Exclusivity Read Post »
Pharma mega-deals dont just hinge on sciencethey hinge on exclusivity math.
Behind every headline acquisition, licensing agreement, or strategic partnership is a quiet question: How long can the seller keep competitors off the fieldand how much value c…
The Four Exclusivities Behind Every Pharma Mega-Deal Read Post »
Patent cliffs arent just a legal eventtheyre a pricing event. Heres how to forecast drug price erosion before it hits.
If youve ever watched a blockbusters revenue curve bend downward almost overnight, you already know the uncomfortable truth: the mark…
Patent Cliff Forecasting: How to Predict Drug Price Erosion Before It Happens Read Post »
Post-Approval Isnt AfterIts the Next Battleground for Drug IP
Most teams treat the moment a drug is approved as the finish line. In reality, its the start of a new phase of riskone where regulatory timelines, patent term realities, and competitive entr…
Get new actionable insights and updates from BiotechBlog
